Magnetar Financial LLC bought a new stake in shares of Atrion Co. (NASDAQ:ATRI – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,668 shares of the medical instruments supplier’s stock, valued at approximately $2,564,000. Magnetar Financial LLC owned about 0.32% of Atrion as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in ATRI. Kayne Anderson Rudnick Investment Management LLC lifted its position in Atrion by 1.0% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 205,393 shares of the medical instruments supplier’s stock valued at $92,926,000 after purchasing an additional 2,111 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Atrion by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 84,876 shares of the medical instruments supplier’s stock worth $39,344,000 after buying an additional 326 shares during the period. Bank of New York Mellon Corp grew its position in shares of Atrion by 3.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 14,921 shares of the medical instruments supplier’s stock worth $6,751,000 after buying an additional 436 shares during the last quarter. Versor Investments LP purchased a new position in shares of Atrion during the second quarter valued at approximately $3,247,000. Finally, Penn Mutual Asset Management LLC bought a new position in shares of Atrion during the fourth quarter valued at approximately $1,949,000. Hedge funds and other institutional investors own 66.19% of the company’s stock.
Atrion Price Performance
Shares of NASDAQ ATRI opened at $459.92 on Tuesday. Atrion Co. has a 1 year low of $274.98 and a 1 year high of $503.24. The stock has a market capitalization of $809.46 million, a P/E ratio of 43.23 and a beta of 0.69. The company’s 50-day moving average is $459.06 and its 200 day moving average is $446.19.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on shares of Atrion in a report on Thursday, September 19th. They issued a “sell” rating on the stock.
Check Out Our Latest Research Report on ATRI
Atrion Profile
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Recommended Stories
- Five stocks we like better than Atrion
- Why Are These Companies Considered Blue Chips?
- The Average 401k Balance by Age Explained
- Best Aerospace Stocks Investing
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What Are Some of the Best Large-Cap Stocks to Buy?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI – Free Report).
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.